STOCK TITAN

[Form 4] Zivo Bioscience, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Positive)
Form Type
4

Zivo Bioscience (ZIVO) reported an insider purchase. Director and 10% owner Laith L. Yaldoo acquired 1,659 shares of common stock on 10/10/2025 at $12.05 per share, held indirectly through HEP Investments LLC. Following the trade, beneficial ownership was 575,095 shares, reported as indirect.

Zivo Bioscience (ZIVO) ha riferito un'acquisizione da insider. Il direttore e proprietario del 10% Laith L. Yaldoo ha acquisito 1.659 azioni di capitale comune il 10/10/2025 al prezzo di 12,05 dollari per azione, detenute indirettamente tramite HEP Investments LLC. A seguito della operazione, la proprietà beneficiaria ammontava a 575.095 azioni, riportate come indirette.

Zivo Bioscience (ZIVO) informó de una compra de insiders. El director y propietario del 10% Laith L. Yaldoo adquirió 1.659 acciones comunes el 10/10/2025 a 12,05 dólares por acción, mantenidas indirectamente a través de HEP Investments LLC. Tras la operación, la propiedad beneficiosa era de 575.095 acciones, reportadas como indirectas.

Zivo Bioscience (ZIVO) 내부자 매입을 보고했습니다. 이사이자 10% 지분 소유자인 Laith L. Yaldoo가 2025년 10월 10일 주당 12,05달러에 1,659주의 보통주를 취득했으며, HEP Investments LLC를 통해 간접적으로 보유했습니다. 거래 후 유익한 소유권은 575,095주로 간접 소유로 보고되었습니다.

Zivo Bioscience (ZIVO) a annoncé un achat par un initié. Le directeur et propriétaire à 10 % Laith L. Yaldoo a acquis 1 659 actions ordinaires le 10/10/2025 à 12,05 dollars par action, détenues indirectement via HEP Investments LLC. À la suite de l'opération, la détention bénéficiaire était de 575 095 actions, indiquées comme indirectes.

Zivo Bioscience (ZIVO) meldete einen Insiderkauf. Der Direktor und 10%-Eigentümer Laith L. Yaldoo erwarb am 10.10.2025 1.659 Stammaktien zum Preis von 12,05 USD je Aktie, indirekt über HEP Investments LLC gehalten. Nach dem Handel betrug die beherrschende Beteiligung 575.095 Aktien, als indirekt gemeldet.

Zivo Bioscience (ZIVO) أبلغت عن شراء من الداخل. قام المدير ومالِك 10% Laith L. Yaldoo بشراء 1,659 سهماً من الأسهم العادية في 10/10/2025 بسعر 12.05 دولاراً للسهم، وتُحفظ بشكل غير مباشر من خلال HEP Investments LLC. بعد الصفقة، بلغت الملكية المستفيدة 575,095 سهماً، وقد أُبلغ عنها باعتبارها غير مباشرة.

Zivo Bioscience (ZIVO) 披露了内幕交易。董事兼10%所有者 Laith L. Yaldoo 于 2025/10/10 以每股 12.05 美元购入 1,659 股普通股,通过 HEP Investments LLC 间接持有。交易后,受益所有权为 575,095 股,报告为间接持有。

Positive
  • None.
Negative
  • None.

Zivo Bioscience (ZIVO) ha riferito un'acquisizione da insider. Il direttore e proprietario del 10% Laith L. Yaldoo ha acquisito 1.659 azioni di capitale comune il 10/10/2025 al prezzo di 12,05 dollari per azione, detenute indirettamente tramite HEP Investments LLC. A seguito della operazione, la proprietà beneficiaria ammontava a 575.095 azioni, riportate come indirette.

Zivo Bioscience (ZIVO) informó de una compra de insiders. El director y propietario del 10% Laith L. Yaldoo adquirió 1.659 acciones comunes el 10/10/2025 a 12,05 dólares por acción, mantenidas indirectamente a través de HEP Investments LLC. Tras la operación, la propiedad beneficiosa era de 575.095 acciones, reportadas como indirectas.

Zivo Bioscience (ZIVO) 내부자 매입을 보고했습니다. 이사이자 10% 지분 소유자인 Laith L. Yaldoo가 2025년 10월 10일 주당 12,05달러에 1,659주의 보통주를 취득했으며, HEP Investments LLC를 통해 간접적으로 보유했습니다. 거래 후 유익한 소유권은 575,095주로 간접 소유로 보고되었습니다.

Zivo Bioscience (ZIVO) a annoncé un achat par un initié. Le directeur et propriétaire à 10 % Laith L. Yaldoo a acquis 1 659 actions ordinaires le 10/10/2025 à 12,05 dollars par action, détenues indirectement via HEP Investments LLC. À la suite de l'opération, la détention bénéficiaire était de 575 095 actions, indiquées comme indirectes.

Zivo Bioscience (ZIVO) meldete einen Insiderkauf. Der Direktor und 10%-Eigentümer Laith L. Yaldoo erwarb am 10.10.2025 1.659 Stammaktien zum Preis von 12,05 USD je Aktie, indirekt über HEP Investments LLC gehalten. Nach dem Handel betrug die beherrschende Beteiligung 575.095 Aktien, als indirekt gemeldet.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
YALDOO LAITH L

(Last) (First) (Middle)
1934 BLOOMFIELD ROAD

(Street)
BLOOMFIELD HILLS MI 48302

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Zivo Bioscience, Inc. [ ZIVO ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/10/2025 P 1,659 A $12.05 575,095 I by HEP Investments LLC
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Laith L. Yaldoo 10/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZIVO report?

A director and 10% owner purchased 1,659 shares of common stock at $12.05 on 10/10/2025.

Who made the purchase in ZIVO (ZIVO)?

The filing is signed by Laith L. Yaldoo, identified as a Director and 10% Owner.

How many ZIVO shares are beneficially owned after the trade?

Following the transaction, the filing reports 575,095 shares beneficially owned.

Was the ZIVO purchase direct or indirect?

Ownership is reported as Indirect (I) through HEP Investments LLC.

What was the transaction code and price for the ZIVO trade?

Transaction code P (open market purchase) at $12.05 per share.

When did the ZIVO insider transaction occur?

The transaction date was 10/10/2025.
Zivo Bioscience Inc

OTC:ZIVO

ZIVO Rankings

ZIVO Latest News

ZIVO Latest SEC Filings

ZIVO Stock Data

49.62M
1.37M
64.06%
0.12%
2.04%
Biotechnology
Healthcare
Link
United States
Troy